Michael Crump

Also affiliated with University of Toronto, Princess Margaret Cancer Centre

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma”.

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

New England Journal of Medicine(2024)10.1056/nejmoa2405888

N/A

3.4DataRank · unranked

211 citations

Michael LeBlanc, Sharon M. Castellino, Hongli Li, Sarah C. Rutherford, Andrew M. Evens +42 more

Impact of High-Dose Chemotherapy on the Ability to Deliver Subsequent Local–Regional Radiotherapy for Breast Cancer: Analysis of Cancer and Leukemia Group B Protocol 9082

Carolina Digital Repository (University of North Carolina at Chapel Hill)(2020)10.17615/pdfa-n953

N/A

0DataRank · unranked

0 citations

Thomas J. FitzGerald, William P. Peters, F. Laurie, Steven L. Seagren, Jinli Ma +13 more

A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia

Clinical Lymphoma Myeloma & Leukemia(2021)10.1016/j.clml.2021.06.011

N/A

0DataRank · unranked

5 citations

Nicole Mittmann, Carolyn Owen, Nizar Abdel‐Samad, Graeme Fraser, Selay Lam +15 more

NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826

Hematological Oncology(2023)10.1002/hon.3163_5

N/A

0DataRank · unranked

21 citations

Michael LeBlanc, Sharon M. Castellino, Huilin Li, Sarah C. Rutherford, Andrew M. Evens +41 more

CCTG LY18‐A phase I master protocol of novel combination therapy for patients with relapsed or refractory lymphoma ‐ the RGDP‐Venetoclax substudy

Hematological Oncology(2023)10.1002/hon.3164_441

N/A

0DataRank · unranked

1 citations

Diego Villa, Annette E. Hay, Nathalie A. Johnson, Michael Crump, Robert Kridel +10 more